Aspergillosis of biliary tract after liver transplantation: A case report

Mycopathologia

Volumn 170, Issue 2, 2010, Pages 117-121

  Yuchong, Chen ^a   Dingheng, Zhu ^a   Zhizhong, Yuan ^a   Hongyu, Yu ^a   Jing, He ^a   Jianghan, Chen ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Aspergillosis; Biliary tract; Leukocytopenia; Organ transplantation

Indexed keywords

FLUCONAZOLE;

ANTIFUNGAL RESISTANCE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FLAVUS; CASE REPORT; CHEMOPROPHYLAXIS; CYTOCHEMISTRY; FATALITY; GENETICS; GROWTH, DEVELOPMENT AND AGING; HEPATOBILIARY SYSTEM; HUMAN; IMMUNOCOMPROMISED PATIENT; ISOLATION AND PURIFICATION; LIVER TRANSPLANTATION; MALE; METHODOLOGY; MICROBIOLOGY; MICROSCOPY; MIDDLE AGED; PATHOLOGY; PROCEDURES;

ASPERGILLOSIS; ASPERGILLUS FLAVUS; BILIARY TRACT; CHEMOPREVENTION; DRUG RESISTANCE, FUNGAL; FATAL OUTCOME; FLUCONAZOLE; HISTOCYTOCHEMISTRY; HUMANS; IMMUNOCOMPROMISED HOST; LIVER TRANSPLANTATION; MALE; MICROSCOPY; MIDDLE AGED;

ASPERGILLUS; ASPERGILLUS FLAVUS;

EID: 77954244684     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-010-9300-y     Document Type: Article

References (27)

1. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore). 2000; 79: 250-60.
2. Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998; 26: 781-803.
3. Marr KA, Patterson T, Denning D. Aspergillosis: pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am. 2002; 16: 875-94.
4. Perfect JR, Cox GM, Lee JY, et al. The impact of culture isolation of Aspergillus species: a hospital-based survey of aspergillosis. Clin Infect Dis. 2001; 33: 1824-33.
5. Walsh TJ, Groll AH. Overview: non-fumigatus species of Aspergillus: perspectives on emerging pathogens in immunocompromised hosts. Curr Opin Investig Drugs. 2001; 2: 1366-7.
6. Christensen H, Nilsson KO, Nettelblad SC, et al. Common bile duct obstruction due to an intraluminal mass of candidiasis in a previously healthy child. Pediatrics. 1986; 77: 858-61.
7. Morris AB, Sands ML, Shiraki M, et al. Gallbladder and biliary tract candidiasis: nine cases and review. Rev Infect Dis. 1990; 12: 483-9.
8. Noack KB, Osmon R, Patts KP, et al. Successful orthotopic liver transplantation in a patient with refractory biliary candidiasis. Gastroenterology. 1991; 101: 1728-30.
9. Kabir S, Rajendran N, Amemiya T, et al. Quantitative measurement of fungal DNA extracted by three different methods using real-time polymerase chain reaction. J Biosci Bioeng. 2003; 96: 337-43.
10. Zhao K, Ping W, Li Q, et al. Aspergillus niger var. taxi, a new species variant of taxol-producing fungus isolated from Taxus cuspidata in China. J Appl Microbiol. 2009; 107: 1202-7.
11. Kleinschmidt-DeMasters BK. Central nervous system aspergillosis: a 20-year retrospective series. Hum Pathol. 2002; 33: 116.
12. Hospenthal DR, Rinaldi MG. Aspergillosis. In: Boucher HW, Patterson TF, editors. Diagnosis and treatment of human mycoses. New Jersey: Humana Press Inc; 2008. p. 181-94.
13. Steven HE, Brent JB, Leslie LB. Aspergillus cholangitis: a late complication after Kasai portoenterostomy. J Pedi Surg. 2002; 37: 923-5.
14. Hajjeh RA, Warnock DW. Counterpoint: invasive aspergillosis and the environment rethinking our approach to prevention. Clin Infect Dis. 2001; 33: 1549-52.
15. Woodcock AA, Steel N, Moore CB, Howard SJ, Custovic A, Denning DW. Fungal contamination of bedding. Allergy. 2006; 61: 140-2.
16. Anaissie EJ, Stratton SL, Dignani MC, et al. Pathogenic moulds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. Blood. 2003; 101: 2542-6.
17. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America (IDSA). Clin Infect Dis. 2008; 46: 327-60.
18. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis. 2001; 32: 358-66.
19. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis. 2001; 33: 641-7.
20. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine. 1999; 78: 123-38.
21. Kusne S, Torre-Cisneros J, Manos R, et al. Factors associated with invasive lung aspergillosis and the significance of positive Aspergillus culture after liver transplantation. J Infect Dis. 1992; 166: 1379-83.
22. Castaldo P, Stratta RJ, Wood RP, et al. Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch Surg. 1991; 126: 149-56.
23. Singh N, Mieles L, Yu VL, et al. Invasive aspergillosis in liver transplant recipients: association with candidemia and consumption coagulopathy and failure of prophylaxis with low-dose amphotericin B. Clin Infect Dis. 1993; 17: 906-8.
24. Paya CV, Hermans PE, Washington JA, et al. Incidence, distribution, and outcome of episodes of infection in 100 orthotopic liver transplantations. Mayo Clin Proc. 1989; 64: 555-64.
25. Playford EG, Webster AC, Sorrell TC, Craig JC. Systematic review and meta-analysis of antifungal agents for preventing fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis. 2006; 25: 549-61.
26. Muñoz P, Torre J, Bouza E, et al. Invasive aspergillosis in transplant recipients. A large multicentric study. In: Program and abstracts of the 36th interscience conference on antimicrobial agents and chemotherapy, New Orleans, Abstract J128. Washington: American Society for Microbiology; 1996. p. 242.
27. Fortún J, Martín-Dávila P, Moreno S, et al. Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients. J Antimicrob Chemother. 2003; 52: 813-9.